Each year, more than 1.2 million Americans suffer a heart attack, one of the top three leading causes of death in the United States.  Despite many significant advances in hospital care of heart attack patients, pre-hospital mortality remains unchanged over the past 40 years.  

Treatment of heart attacks within the first 1–2 hours with a thrombolytic agent, percutaneous coronary intervention, or a GPIIb/IIIa (αIIbβ3) antagonist decreases mortality and the later development of heart failure. 

We are developing a novel small molecule inhibitor of the Platelet GPIIb/IIIa receptor, designed to be easily administered subcutaneously by auto-injector to facilitate its use as the first point of contact treatment for heart attacks, specifically ST Segment Elevated Myocardial Infarction (STEMI).